Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer
Anticancer Research · 2025-06 · 45 (6) · 2575-2586
DOI: 10.21873/anticanres.17629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 27.05.2025. Verfasst von Han Gyeol Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immune Checkpoint Inhibitors, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Triple-negative breast cancer (TNBC) is an aggressive malignancy with few available targeted therapies. In this study, we examined the predictive power of several biomarkers, comprising the IMmunotherapy Against GastrIc Cancer (IMAGiC) model, PD-L1 combined positive score (CPS), intra-tumoral tumor-infiltrating lymphocytes (iTILs), and stromal TILs (sTILs), in an Asian population of patients with metastatic TNBC treated with immunotherapy. PATIENTS AND METHODS: Thirty-one metastatic TNBC patients receiving immunotherapy were analyzed. For measuring expression levels of the mRNA of four immune-related genes in the IMAGiC test, quantitative real-time polymerase chain reaction was used. TIL detection and quantification were conducted using Lunit SCOPE IO, which is an AI-powered spatial TIL analyzer. RESULTS: Patients were classified into IMAGiC responder and non-responder groups according to IMAGiC score cut-off value. There were significantly more clinical responders [complete (CR) or partial (PR) response] in the IMAGiC responder group than in the IMAGiC non-responder group (50% vs. 15.3%, p=0.05). Area under the curve (AUC) values were calculated to examine the predictive value of the IMAGiC score, PD-L1 CPS, iTILs, and sTILs, for response to immunotherapy. The AUC values of the IMAGiC group and score were 0.684 and 0.632, respectively. When the IMAGiC group and iTIL level were combined, the highest AUC value of 0.755 was obtained. CONCLUSION: The combination of IMAGiC and iTILs as a biomarker can guide clinical decisions in the immunotherapy of metastatic TNBCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
- Center of Companion Diagnostics, Samsung Medical Center, Seoul, Republic of Korea.
- Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Lunit, Seoul, Republic of Korea.
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; eunyoon.cho@samsung.com.
Zitieren
APA
Kim, H. G., Kang, S. Y., Kim, K. M., Kim, J. Y., Park, Y. H., Ahn, J. S., Im, Y. H., Lim, Y., Song, S., Paeng, K., & Cho, E. Y. (2025). Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer. Anticancer Research, 45(6), 2575-2586. https://doi.org/10.21873/anticanres.17629
Vancouver
Kim HG, Kang SY, Kim KM, Kim JY, Park YH, Ahn JS, et al. Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer. Anticancer Research. 2025;45(6):2575-2586. doi:10.21873/anticanres.17629
BibTeX
@article{Kim2025,
author = {Kim, Han Gyeol and Kang, So Young and Kim, Kyoung-Mee and Kim, Ji-Yeon and Park, Yeon Hee and Ahn, Jin Seok and Im, Young-Hyuck and Lim, Yoojoo and Song, Sanghoon and Paeng, Kyunghyun and Cho, Eun Yoon},
title = {Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer},
journal = {Anticancer Research},
year = {2025},
volume = {45},
number = {6},
pages = {2575--2586},
doi = {10.21873/anticanres.17629}
}
EUVIMED